Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Callis

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
PCR Methods and Applications|June 1, 1995
Nonradioactive multiplex PCR screening strategy for the simultaneous detection of multiple low-density lipoprotein receptor gene mutationsM J Kotze, L Theart, M Callis, et al.
Molecular and Cellular Probes|July 17, 1998
Mutation analysis in familial hypercholesterolemia patients of different ancestries: identification of three novel LDLR gene mutationsM Callis, S Jansen, R Thiart, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 1998
Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin IIP J Pagano, J K Clark, M E Cifuentes-Pagano, et al.
Regulatory Toxicology and Pharmacology : RTP|April 6, 2010
In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substancesJoel P Bercu, Stuart M Morton, J Thom Deahl, et al.
British Journal of Haematology|February 13, 2001
Hereditary non-spherocytic haemolytic anaemia due to red blood cell glutathione synthetase deficiency in four unrelated patients from Spain: clinical and molecular studiesJ L Corrons, R Alvarez, A Pujades, et al.
Regulatory Toxicology and Pharmacology : RTP|August 14, 2022
Setting impurity limits for endogenous substances: Recommendations for a harmonized procedure and an example using fatty acidsRobert A Jolly, Suren Bandara, Joel Bercu, et al.
Regulatory Toxicology and Pharmacology : RTP|October 10, 2020
Considerations when deriving compound-specific limits for extractables and leachables from pharmaceutical products: Four case studiesPatricia Parris, Elizabeth A Martin, Brad Stanard, et al.
PDA Journal of Pharmaceutical Science and Technology|January 15, 2022
Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTCs) Relevant to Parenteral Extractables and Leachables (E&Ls)Melisa J Masuda-Herrera, Joel P Bercu, Thomas H Broschard, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
PCR Methods and Applications|June 1, 1995
Nonradioactive multiplex PCR screening strategy for the simultaneous detection of multiple low-density lipoprotein receptor gene mutationsM J Kotze, L Theart, M Callis, et al.
Molecular and Cellular Probes|July 17, 1998
Mutation analysis in familial hypercholesterolemia patients of different ancestries: identification of three novel LDLR gene mutationsM Callis, S Jansen, R Thiart, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 1998
Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin IIP J Pagano, J K Clark, M E Cifuentes-Pagano, et al.
Regulatory Toxicology and Pharmacology : RTP|April 6, 2010
In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substancesJoel P Bercu, Stuart M Morton, J Thom Deahl, et al.
British Journal of Haematology|February 13, 2001
Hereditary non-spherocytic haemolytic anaemia due to red blood cell glutathione synthetase deficiency in four unrelated patients from Spain: clinical and molecular studiesJ L Corrons, R Alvarez, A Pujades, et al.
Regulatory Toxicology and Pharmacology : RTP|August 14, 2022
Setting impurity limits for endogenous substances: Recommendations for a harmonized procedure and an example using fatty acidsRobert A Jolly, Suren Bandara, Joel Bercu, et al.
Regulatory Toxicology and Pharmacology : RTP|October 10, 2020
Considerations when deriving compound-specific limits for extractables and leachables from pharmaceutical products: Four case studiesPatricia Parris, Elizabeth A Martin, Brad Stanard, et al.
PDA Journal of Pharmaceutical Science and Technology|January 15, 2022
Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTCs) Relevant to Parenteral Extractables and Leachables (E&Ls)Melisa J Masuda-Herrera, Joel P Bercu, Thomas H Broschard, et al.
Pageof 4